{"a":[{"_":"‘It’s making a difference’: Madrigal CEO talks strategy behind MASH shopping spree ","$":{"href":"/biotech/its-making-difference-madrigal-ceo-talks-strategy-behind-mash-shopping-spree","hreflang":"en"}}]}

Summary

Madrigal Pharmaceuticals is pursuing a strategic acquisition strategy in 2026, shopping for drugs to complement its MASH therapy Rezdiffra as it progresses toward blockbuster status. The company is seeking complementary assets to expand its portfolio in the metabolic disease space.